Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when COCH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsEnvoy Medical shareholders approve 7.2M share expansion for employee compensation plans
Filed May 18, 2026 · Period ending May 12, 2026 · ~1 min read
Key Changes
-
medium
Stockholders authorized 6 million additional shares for the 2023 Equity Incentive Plan, expanding the pool available for employee stock grants and options. This represents potential dilution but is standard for growth-stage companies attracting talent.
Item 5.07 verify on EDGAR → -
medium
An additional 1.2 million shares were approved for the Employee Stock Purchase Plan, bringing total new shares authorized across both plans to 7.2 million. Both amendments became effective immediately upon May 12, 2026 stockholder approval.
Item 5.07 verify on EDGAR → -
medium
Shareholders ratified warrants issued in February 2026 to comply with Nasdaq Listing Rule 5635(d). The warrants were already issued; this vote provides required regulatory approval after the fact.
Item 5.07 verify on EDGAR → -
low
Brent T. Lucas and Susan J. Kantor were elected as Class III directors with terms extending to 2029. Both received strong shareholder support with over 46 million votes each.
Item 5.07 verify on EDGAR →
Summary
Envoy Medical's annual meeting on May 12, 2026 resulted in stockholder approval of significant expansions to employee compensation programs. The company secured authorization for 6 million additional shares under its Equity Incentive Plan and 1.2 million shares under its Employee Stock Purchase Plan, totaling 7.2 million new shares available for employee compensation.
While this represents incremental dilution to existing shareholders, such expansions are typical for growth-stage medical device companies that need competitive equity packages to attract and retain specialized talent. Shareholders also ratified warrants that were issued in a February 2026 transaction, providing the after-the-fact approval required by Nasdaq listing rules.
The routine nature of this ratification suggests the warrant issuance was already disclosed in prior filings. The meeting also saw the election of two Class III directors to three-year terms. Retail investors should monitor how quickly the company deploys these newly authorized shares and whether the equity compensation aligns with business milestones and revenue growth. The next quarterly filing should provide updated share count data showing the dilutive impact of these authorizations.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
an amendment to the Company’s 2023 Equity Incentive Plan (the “Equity Incentive Plan”) to authorize an additional 6,000,000 shares of the Company’s Class A Common Stock, par value $0.0001 per share (“Common Stock”), for issuance under the Equity Incentive Plan (the “Equity Plan Amendment”)
Stockholders approved an amendment to the 2023 Equity Incentive Plan that authorizes an additional 6 million shares of Class A Common Stock for issuance. This increases the pool of shares available for employee equity compensation grants. The amendment became effective immediately upon stockholder approval at the May 12, 2026 Annual Meeting.
Added in current filing · verify on EDGAR →
an amendment to the Company’s 2023 Employee Stock Purchase Plan (the “Employee Stock Purchase Plan”) to authorize an additional 1,200,000 shares of Common Stock for issuance under the Employee Stock Purchase Plan (the “Purchase Plan Amendment”)
Stockholders approved an amendment to the 2023 Employee Stock Purchase Plan that authorizes an additional 1.2 million shares of Common Stock for issuance. This expands the share pool available for employee stock purchases through the ESPP program. Like the equity plan amendment, this became effective immediately upon stockholder approval.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Annual meeting results: directors elected, auditor ratified, equity plans expanded by 7.2M shares, and February 2026 warrant issuance approved.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company’s stockholders elected two Class III director nominees, Brent T. Lucas and Susan J. Kantor, to the Company’s Board of Directors to hold office until the earlier of the 2029 annual meeting of stockholders, the election of such director’s successor, or such director’s death, resignation or removal
Shareholders elected Brent T. Lucas and Susan J. Kantor as Class III directors with terms extending to 2029. Lucas received 47,216,205 votes for and Kantor received 46,961,571 votes for, both passing comfortably.
Event · Item 9.01 — Financial Statements and Exhibits
Envoy Medical filed amendments to its 2023 equity incentive and employee stock purchase plans with no material business impact disclosed.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
Amended No. 1 to Envoy Medical, Inc. Amended and Restated 2023 Equity Incentive Plan
The company filed an amendment to its equity incentive plan. The 8-K provides no details about what changed in the plan, such as share reserve increases, eligibility modifications, or vesting terms. This is a procedural filing documenting the amendment's existence.
Added in current filing · verify on EDGAR →
Amended No. 1 to Envoy Medical, Inc. 2023 Employee Stock Purchase Plan
The company filed an amendment to its employee stock purchase plan. No substantive details about the amendment are disclosed in the 8-K body. This is a routine exhibit filing with no immediate material impact described.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 26, 2026 · How we verify